Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Conavi Medical ( (TSE:CNVI) ) is now available.
Conavi Medical announced its fiscal Q3 2025 results, highlighting successful validation testing of its Novasight Hybrid™ system and a $20 million financing round that bolsters its financial position ahead of a planned U.S. launch. The company remains on track for a U.S. FDA 510(k) submission in Q3 2025, with expectations of launching in the first half of 2026. Recent academic publications emphasize the growing importance of intravascular imaging, underscoring the potential impact of Conavi’s hybrid IVUS/OCT technology on patient care and the broader cardiovascular market.
The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.
More about Conavi Medical
Conavi Medical Corp. is a commercial-stage medical device company that specializes in designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures.
Average Trading Volume: 48,049
Technical Sentiment Signal: Sell
Current Market Cap: C$23.78M
For a thorough assessment of CNVI stock, go to TipRanks’ Stock Analysis page.